On 16 June 2020, the US Food and Drug Administration (FDA) granted accelerated
approval to pembrolizumab for the treatment of 'adult and pediatric patients with …

Abstract Treatment with immune checkpoint inhibitors targeting programmed cell death
protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer …

Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …

In less than a decade, half a dozen immune checkpoint inhibitors have been approved and
are currently revolutionising the treatment of many cancer (sub) types. With the clinical …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

Although approved programmed cell death protein (PD)-1 inhibitors show durable
responses, clinical benefits to these agents are only seen in one-third of patients in most …

Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies.
CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we …

Immune checkpoint inhibitors (ICIs) have changed therapeutic algorithms in several
malignancies, although intrinsic and secondary resistance is still an issue. In this context, the …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering
studies to understand the molecular and cellular wiring of response and resistance. Our …